Navigation Links
Angiotech and Symphony Medical Announce Licensing Agreement
Date:1/17/2008

lation device. The concept is protected by a number of patents which are currently pending.

"We are excited about the opportunity to work with Angiotech's biomaterial to address a large unmet clinical need in POAF. According to numerous clinical studies, on average, 40 percent of patients who undergo CABG and coronary valve surgeries develop atrial fibrillation. Based on the success of our preclinical animal model, we have already received EU and Institutional Review Board approval for our 60 patient multi-center 'randomized safety study' in Germany and expect to begin enrolling patients in the first quarter of 2008," said Raymond W. Cohen, CEO of Symphony.

Under the terms of the agreement, Angiotech has been granted an equity position in Symphony Medical in exchange for the exclusive license of Angiotech's technology in the field of POAF. In addition, Angiotech will receive a royalty on end-user product sales should the product receive regulatory approval and is commercialized.

About Post-Operative Atrial Fibrillation (AF)(1)

Atrial fibrillation is a common arrhythmia following open heart surgery that is associated with increased morbidity and mortality. Patients who develop postoperative atrial fibrillation are more likely to have other postoperative complications such as peri-operative MI, CHF and respiratory failure(2). Postoperative atrial fibrillation is associated with longer ICU and hospital stays and consequently, the economic cost can be considerable(3).

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,600 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit http://www.ang
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
3. Angiotech to participate in RBC 2007 Healthcare Conference
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... 1, 2015 About Bio-alcohols ... sugar or cellulose. Bio-alcohols are primarily used in the ... a replacement for gasoline in cars. Technavio,s analysts forecast ... of 9 percent over the period 2014-2019. ... can be segmented into five: transportation, infrastructure, medical, and ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Regis ... and manufacturing of chiral stationary phases (CSPs) for ... for its current and presenting solutions for new ... its portfolio. This valuable addition to its core ... effective advantage that can tackle projects for the ...
(Date:6/1/2015)... ROCHESTER, Minn. and SOUTH SAN ... Baxter Ventures, the venture arm of Baxter International Inc. ... Pharmaceutical Development, LLC ("VPD") today announced the formation of ... model initiated by Baxter Ventures to focus on the ... of immunology, hematology, and oncology. Following the spin-off of ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Global Bio-alcohols Market 2015-2019 2Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5
... Campaign for Cancer Prevention (CCP) began in 2007 with the ... about preventing cancer.  It has now grown to a more ... the social media platform, Causes.com. Nearly five years later, CCP ... a Harvard Medical School flagship teaching hospital, with all campaign ...
... 2011 Redwood Bioscience, a biopharmaceutical company developing ... conjugates, announced the appointment of Peter Van Vlasselaer, ... Directors.  In this role, Dr. Van Vlasselaer will ... development as well as corporate strategy.  Dr. Van ...
... LAGUNA NIGUEL, Calif., Oct. 3, 2011 Inspiration Biopharmaceuticals, ... (EMA) has validated and accepted the filing of the ... factor IX (FIX) product for the treatment and prevention ... so, the EMA has verified that it will begin ...
Cached Biology Technology:Campaign for Cancer Prevention Connects 6 Million+ Members on Facebook Causes to Groundbreaking Research at Brigham and Women's Hospital 2Campaign for Cancer Prevention Connects 6 Million+ Members on Facebook Causes to Groundbreaking Research at Brigham and Women's Hospital 3Campaign for Cancer Prevention Connects 6 Million+ Members on Facebook Causes to Groundbreaking Research at Brigham and Women's Hospital 4Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman 2Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B 2Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B 3
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/26/2015)... Research and Markets ( ... "Saudi Arabia Biometric Systems Market Forecast and ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... to grow at over 22% CAGR through 2020 ... the surging demand for better biometric technologies in ...
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... healthy diets through adolescence than their peers who do not drink ... study showed that girls who drank soda at age five had ... duration of the study, which ended at age 15. Girls who ... nutritional requirements, but their diets were healthier. The difference between ...
... The WHO Fracture Risk Assessment Tool (FRAX) is now easily ... access and easy to use in any clinical setting. ... year probability of a major osteoporotic event, The 10 year ... users, NOGG guidance is accessible. This provides a guide for ...
... WASHINGTON, DC A new analysis by the ... that the U.S. government has spent around $430 million ... the Department of Energy funding a majority of the ... European Union and three individual European countries the ...
Cached Biology News:Early consumption of soda indicator of unhealthy diet 2Early consumption of soda indicator of unhealthy diet 3
... to significantly increase the shelf life of ... increased at room temperature storage conditions in ... is subjected to 0.45 micron filtration, and ... formulation insures consistently high levels of activity ...
... ThermoStat Plus accurately and conveniently controls the temperature ... maintains different temperature levels up to 99 C*, ... temperatures as low as 5 C. The thermoblocks ... ml tubes, and microplates enable a high degree ...
... to significantly increase the shelf life of ... increased at room temperature storage conditions in ... is subjected to 0.2 micron filtration, and ... formulation insures consistently high levels of activity ...
...
Biology Products: